[go: up one dir, main page]

WO2024020063A3 - Anti-hrf antibodies - Google Patents

Anti-hrf antibodies Download PDF

Info

Publication number
WO2024020063A3
WO2024020063A3 PCT/US2023/028081 US2023028081W WO2024020063A3 WO 2024020063 A3 WO2024020063 A3 WO 2024020063A3 US 2023028081 W US2023028081 W US 2023028081W WO 2024020063 A3 WO2024020063 A3 WO 2024020063A3
Authority
WO
WIPO (PCT)
Prior art keywords
hrf
antibodies
monoclonal antibodies
therapeutically
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/028081
Other languages
French (fr)
Other versions
WO2024020063A2 (en
Inventor
Toshiaki Kawakami
Toshiaki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Abwiz Bio Inc
Original Assignee
La Jolla Institute for Allergy and Immunology
Abwiz Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Institute for Allergy and Immunology, Abwiz Bio Inc filed Critical La Jolla Institute for Allergy and Immunology
Publication of WO2024020063A2 publication Critical patent/WO2024020063A2/en
Publication of WO2024020063A3 publication Critical patent/WO2024020063A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Monoclonal antibodies reactive to human histamine releasing factor (HRF) protein and fragments thereof are provided for use diagnostically and therapeutically. These monoclonal antibodies are shown to be strong inhibitors of HRF-IGE interactions and the inflammatory response.
PCT/US2023/028081 2022-07-19 2023-07-18 Anti-hrf antibodies Ceased WO2024020063A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263390603P 2022-07-19 2022-07-19
US63/390,603 2022-07-19

Publications (2)

Publication Number Publication Date
WO2024020063A2 WO2024020063A2 (en) 2024-01-25
WO2024020063A3 true WO2024020063A3 (en) 2024-03-07

Family

ID=89618455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/028081 Ceased WO2024020063A2 (en) 2022-07-19 2023-07-18 Anti-hrf antibodies

Country Status (1)

Country Link
WO (1) WO2024020063A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119978135B (en) * 2025-01-02 2025-11-21 生物岛实验室 Specific antibodies against Sumo-tagged proteins, their preparation methods and applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180312588A1 (en) * 2017-04-24 2018-11-01 Kite Pharma, Inc. Humanized antigen-binding domains and methods of use
US20200369750A1 (en) * 2010-03-31 2020-11-26 La Jolla Institute For Allergy And Immunology Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation
US20220056124A1 (en) * 2018-09-05 2022-02-24 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
US20220135701A1 (en) * 2019-04-19 2022-05-05 Genentech, Inc. Anti-mertk antibodies and their methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200369750A1 (en) * 2010-03-31 2020-11-26 La Jolla Institute For Allergy And Immunology Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation
US20180312588A1 (en) * 2017-04-24 2018-11-01 Kite Pharma, Inc. Humanized antigen-binding domains and methods of use
US20220056124A1 (en) * 2018-09-05 2022-02-24 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
US20220135701A1 (en) * 2019-04-19 2022-05-05 Genentech, Inc. Anti-mertk antibodies and their methods of use

Also Published As

Publication number Publication date
WO2024020063A2 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
Yuan et al. Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis
Mao et al. Human placental trophoblasts express the immunosuppressive cytokine IL-35
Yusuf et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis
Li et al. Aconitine: a potential novel treatment for systemic lupus erythematosus
WO2024020063A3 (en) Anti-hrf antibodies
AU6760700A (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
Konttinen et al. Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis.
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
Katsiari et al. Immunotherapy of systemic sclerosis
Hori et al. Intravenous immunoglobulin (IVIg) acts directly on conventional T cells to suppress T cell receptor signaling
TR200102877T2 (en) Anti-idiotypic antibodies against antibodies that inhibit the binding of immunoglobulin to its own high affinity receptor.
WO2022197914A3 (en) Stem cell factor antibodies and methods of use thereof
JPH02288836A (en) Inhibitor of immunocyte proliferation
EP4031176A4 (en) Anti-stem cell factor antibodies and methods of use thereof in renal disease
Bruneau et al. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation
Gorlier et al. Serum level of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a biomarker of synovitis in rheumatoid arthritis
WO2024030956A3 (en) Cd39-specific binding agents and methods of using the same
WO2024086684A3 (en) Chemokine receptor 8 (ccr8) antibodies
CA3267516A1 (en) Monoclonal antibodies to arabinomannan (am), groel2, and lprg and methods of use
Brambilla et al. Coexistence of Kaposi’s sarcoma and psoriasis: is there a hidden relationship?
WO2024173865A3 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
CA3260354A1 (en) Anti-slc34a2 monoclonal antibodies and uses thereof
CA3265572A1 (en) Anti-monomethyl auristatin antibodies and antibody fragments
WO2023097219A3 (en) Anti-idiotype antibodies
CA3248984A1 (en) Anti-alk1 antibodies and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23843640

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23843640

Country of ref document: EP

Kind code of ref document: A2